Matching articles for "pulmonary arterial hypertension"
Issue 1748 · February 16, 2026
A Treprostinil Inhaler (Yutrepia) for Pulmonary Hypertension

Yutrepia (Liquidia), a dry powder inhaler formulation of the prostacyclin analog treprostinil, has been approved by the FDA to improve exercise ability in adults with pulmonary arterial hypertension (PAH; WHO…

Med Lett Drugs Ther. 2026 Feb 16; 68(1748):27-8 doi:10.58347/tml.2026.1748b
Yutrepia (Liquidia), a dry powder inhaler formulation of the prostacyclin analog treprostinil, has been approved by the FDA to improve exercise ability in adults with pulmonary arterial hypertension (PAH; WHO Group 1) or pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3). Tyvaso DPI , another treprostinil dry powder inhaler, was approved earlier for the same indication.
Issue 1737 · September 15, 2025 Free
In Brief: Embryotoxicity REMS Removal for Endothelin Receptor Antagonists

The FDA has removed the Risk Evaluation and Mitigation Strategy (REMS) requirement for the endothelin receptor antagonists ambrisentan ( Letairis , and generics), bosentan ( Tracleer , and generics),…

Med Lett Drugs Ther. 2025 Sep 15; 67(1737):152 doi:10.58347/tml.2025.1737e
The FDA has removed the Risk Evaluation and Mitigation Strategy (REMS) requirement for the endothelin receptor antagonists ambrisentan ( Letairis , and generics), bosentan ( Tracleer , and generics), macitentan ( Opsumit , and generics; Opsynvi) , and aprocitentan (Tryvio) , and the endothelin receptor antagonist and angiotensin II receptor antagonist sparsentan (Filspari) that was initially implemented because of a possible risk of embryofetal toxicity.
Issue 1707 · July 22, 2024
Iloprost (Aurlumyn) for Frostbite

The FDA has approved Aurlumyn (Eicos Sciences), an IV formulation of the prostacyclin analog iloprost, to reduce the risk of digit amputation in adults with severe frostbite. Iloprost is the first drug to be…

Med Lett Drugs Ther. 2024 Jul 22; 66(1707):114 doi:10.58347/tml.2024.1707b
The FDA has approved Aurlumyn (Eicos Sciences), an IV formulation of the prostacyclin analog iloprost, to reduce the risk of digit amputation in adults with severe frostbite. Iloprost is the first drug to be approved by the FDA for treatment of severe frostbite; it has been used off-label for this indication in the EU and elsewhere for decades. In the US, iloprost is also available as an inhaled formulation (Ventavis) for treatment of pulmonary arterial hypertension.
Issue 1702 · May 13, 2024
Sotatercept (Winrevair) for Pulmonary Arterial Hypertension

The FDA has approved sotatercept-csrk ( Winrevair – Merck), a first-in-class activin signaling inhibitor, to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical…

Med Lett Drugs Ther. 2024 May 13; 66(1702):73-5 doi:10.58347/tml.2024.1702a
The FDA has approved sotatercept-csrk ( Winrevair – Merck), a first-in-class activin signaling inhibitor, to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening events in adults with WHO Group 1 pulmonary arterial hypertension (PAH).
Issue 1488 · February 15, 2016
Selexipag (Uptravi) for Pulmonary Arterial Hypertension

The FDA has approved selexipag ( Uptravi – Actelion), an oral selective prostacyclin IP receptor agonist, for treatment of pulmonary arterial hypertension (PAH). Treprostinil (Orenitram) , an oral…

Med Lett Drugs Ther. 2016 Feb 15; 58(1488):21-3
The FDA has approved selexipag ( Uptravi – Actelion), an oral selective prostacyclin IP receptor agonist, for treatment of pulmonary arterial hypertension (PAH). Treprostinil (Orenitram) , an oral prostacyclin analog, was approved earlier for this indication.
Issue 1485 · January 4, 2016
Ambrisentan (Letairis) and Tadalafil (Adcirca) for Pulmonary Arterial Hypertension

The FDA has approved the use of ambrisentan (Letairis) and tadalafil (Adcirca) together for treatment of pulmonary arterial hypertension (PAH). It is the first 2-drug regimen to be approved for this indication.

Med Lett Drugs Ther. 2016 Jan 4; 58(1485):2-4
The FDA has approved the use of ambrisentan (Letairis) and tadalafil (Adcirca) together for treatment of pulmonary arterial hypertension (PAH). It is the first 2-drug regimen to be approved for this indication.
Issue 1437 · March 3, 2014
Riociguat (Adempas) for Pulmonary Hypertension

The FDA has approved the sGC stimulator riociguat (rye" oh sig' ue at; Adempas – Bayer) for oral treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH)…

Med Lett Drugs Ther. 2014 Mar 3; 56(1437):17-9
The FDA has approved the sGC stimulator riociguat (rye" oh sig' ue at; Adempas – Bayer) for oral treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) following surgery or when surgery is not an option. It is the first drug to be approved for treatment of CTEPH.
Issue 1436 · February 17, 2014
Macitentan (Opsumit) for Pulmonary Arterial Hypertension

The FDA has approved macitentan (ma" si ten' tan; Opsumit – Actelion), for oral treatment of pulmonary arterial hypertension (PAH). Macitentan is the second nonselective endothelin receptor antagonist…

Med Lett Drugs Ther. 2014 Feb 17; 56(1436):15-6
The FDA has approved macitentan (ma" si ten' tan; Opsumit – Actelion), for oral treatment of pulmonary arterial hypertension (PAH). Macitentan is the second nonselective endothelin receptor antagonist approved for PAH. It is a derivative of bosentan (Tracleer) , which is also manufactured by Actelion, and is scheduled to become available generically in 2015. Riociguat (Adempas) , another new drug for this indication, will be reviewed in a future issue. Volibris
Issue 1377 · November 14, 2011
Tadalafil (Cialis) for Signs and Symptoms of Benign Prostatic Hyperplasia

The FDA has approved the use of the phosphodiesterase-5 (PDE-5) inhibitor tadalafil ( Cialis – Lilly) for treatment of signs and symptoms of benign prostatic hyperplasia (BPH) in men with or without erectile…

Med Lett Drugs Ther. 2011 Nov 14; 53(1377):89-90
The FDA has approved the use of the phosphodiesterase-5 (PDE-5) inhibitor tadalafil ( Cialis – Lilly) for treatment of signs and symptoms of benign prostatic hyperplasia (BPH) in men with or without erectile dysfunction. Tadalafil is approved for use under another brand name (Adcirca) for treatment of pulmonary arterial hypertension. The other PDE-5 inhibitors available in the US for treatment of erectile dysfunction (sildenafil [Viagra] ; vardenafil [Levitra] ) have also been reported to be effective for treatment of BPH signs and symptoms, but have not been approved for this indication by the FDA.
Issue 1324 · November 2, 2009
Tadalafil (Adcirca) for Pulmonary Arterial Hypertension

The FDA has approved use of tadalafil ( Adcirca - Lilly/United Therapeutics) for treatment of pulmonary arterial hypertension (PAH).

Med Lett Drugs Ther. 2009 Nov 2; 51(1324):87-8
The FDA has approved use of tadalafil ( Adcirca - Lilly/United Therapeutics) for treatment of pulmonary arterial hypertension (PAH).
Issue 1283 · April 7, 2008
Tadalafil (Cialis) Once a Day for Erectile Dysfunction

The phosphodiesterase type 5 (PDE5) inhibitor tadalafil ( Cialis - Lilly) is now being promoted for once daily treatment of erectile dysfunction. Tadalafil differs from sildenafil ( Viagra ) and vardenafil…

Med Lett Drugs Ther. 2008 Apr 7; 50(1283):27-8
The phosphodiesterase type 5 (PDE5) inhibitor tadalafil ( Cialis - Lilly) is now being promoted for once daily treatment of erectile dysfunction. Tadalafil differs from sildenafil ( Viagra ) and vardenafil (Levitra) , the other PDE5 inhibitors marketed for erectile dysfunction in the US, in having a much longer duration of action.
Issue 1272 · October 22, 2007
Ambrisentan (Letairis) for Pulmonary Arterial Hypertension

Ambrisentan ( Letairis - Gilead), a selective endothelin type A (ET A ) receptor antagonist, has been approved by the FDA for treatment of symptomatic patients (WHO class II or III) with pulmonary arterial…

Med Lett Drugs Ther. 2007 Oct 22; 49(1272):87-8
Ambrisentan ( Letairis - Gilead), a selective endothelin type A (ET A ) receptor antagonist, has been approved by the FDA for treatment of symptomatic patients (WHO class II or III) with pulmonary arterial hypertension (PAH).
Issue 1215 · August 15, 2005
Sildenafil (Revatio) for Pulmonary Arterial Hypertension

The Medical Letter reported last year that sildenafil ( Viagra - Pfizer) appeared to be effective for idiopathic pulmonary arterial hypertension (PAH), but confirmation from a controlled trial was needed. Now…

Med Lett Drugs Ther. 2005 Aug 15; 47(1215):65-7
The Medical Letter reported last year that sildenafil ( Viagra - Pfizer) appeared to be effective for idiopathic pulmonary arterial hypertension (PAH), but confirmation from a controlled trial was needed. Now the results of such a study are about to be published, and the drug has been approved by the FDA for this indication under the trade name Revatio .
Issue 1139 · September 16, 2002
Treprostinil (Remodulin) for Pulmonary Arterial Hypertension

Treprostinil sodium (tre prost' in il; Remodulin - United Therapeutics), a prostacyclin analogue, has been approved by the FDA for continuous subcutaneous (SC) treatment of patients with pulmonary arterial…

Med Lett Drugs Ther. 2002 Sep 16; 44(1139):80-2
Treprostinil sodium (tre prost' in il; Remodulin - United Therapeutics), a prostacyclin analogue, has been approved by the FDA for continuous subcutaneous (SC) treatment of patients with pulmonary arterial hypertension who have dyspnea on more than minimal exertion (NYHA Class II-IV).
Issue 1127 · April 1, 2002
Bosentan (Tracleer) for Pulmonary Arterial Hypertension

Bosentan ( Tracleer - Actelion), a non-peptide endothelin receptor antagonist, has been approved by the FDA for oral treatment of patients who have pulmonary arterial hypertension (PAH) with symptoms of…

Med Lett Drugs Ther. 2002 Apr 1; 44(1127):30-2
Bosentan ( Tracleer - Actelion), a non-peptide endothelin receptor antagonist, has been approved by the FDA for oral treatment of patients who have pulmonary arterial hypertension (PAH) with symptoms of dyspnea at rest or with minimal exertion.